scispace - formally typeset
L

Lorenzo G. Mantovani

Researcher at University of Milan

Publications -  361
Citations -  38356

Lorenzo G. Mantovani is an academic researcher from University of Milan. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 51, co-authored 324 publications receiving 26740 citations. Previous affiliations of Lorenzo G. Mantovani include University of Naples Federico II & University of Milano-Bicocca.

Papers
More filters
Journal ArticleDOI

Phm5 assessment of health-related quality of life in patients with haemophilia with the newly developed haemophilia-specific instrument haem-a-qol

TL;DR: Haem-A-QoL is a short and well-accepted questionnaire and shows quite satisfactory psychometric characteristics (reliability, validity) and is important to understand specific problems of haemophilic patients and to improve their treatment.
Journal ArticleDOI

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up.

TL;DR: In this paper, the authors investigated the response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers (HCWs) in an Italian teaching hospital, where 444 participants were surveyed with either multiple RT-PCR assays for detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs or serology testing for the research of virus-specific immunoglobulins.
Journal ArticleDOI

Cardiac resynchronization therapy : a cost or an investment?

TL;DR: Clinical judgment in the context of current evidence supporting the benefits of cardioverter-defibrillators may provide a rational basis for choosing between CRT-P andCRT-D, which appears to meet the $50 000/QALY benchmark commonly used for health-care interventions in the USA, as well as similar thresholds used in Europe.
Journal ArticleDOI

Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE.

TL;DR: In rivaroxaban-treated patients, rates for the primary outcomes were low, suggesting that patients administered rivroxaban were a good prognosis group, and the choice of anticoagulant varied with cancer type.